tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrol-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrol-1-carboxylate
• 英文别名: tert-butyl2-(5-bromopyridin-3-yl)-1H-pyrrol-1-carboxylate；tert-butyl 2-(5-bromopyridin-3-yl)pyrrole-1-carboxylate
• 化学式: C₁₄H₁₅BrN₂O₂
• 分子量: 323.189
• InChiKey: QSAGKXVHFJRBQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,5-二溴吡啶 、 1-Boc-吡咯-2-硼酸 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以73 mg的产率得到tert-butyl 2-(5-bromopyridin-3-yl)-1H-pyrrol-1-carboxylate
  参考文献：
  名称：

  NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

  摘要：

  公开号：

  EP2589592B1

文献信息

• Nicotinamide derivative or salt thereof
  申请人：Fujiwara Hideyasu

  公开号：US08772320B2

  公开（公告）日：2014-07-08

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异Syk抑制活性的化合物和药物组合物。本发明提供了以下式子（I）所表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每个都可以选择性地具有至少一个取代基；R3表示芳基或杂环基，每个都可以选择性地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起选择性地形成一个带有至少一个取代基的环状氨基团）或其盐，以及用于治疗Syk相关疾病的药物组合物，其包括该烟酰胺衍生物或其盐。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• US8772320B2
  申请人：——

  公开号：US8772320B2

  公开（公告）日：2014-07-08
• US8809371B2
  申请人：——

  公开号：US8809371B2

  公开（公告）日：2014-08-19
• US8895585B2
  申请人：——

  公开号：US8895585B2

  公开（公告）日：2014-11-25